Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 3/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 3/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946380 | 0.85 | HTR3E (0.55) | MEN1KMT2AGRM4HPGDNPC1 | |
| SCHEMBL9045874 | 0.82 | EGFR (0.52) | GRM4 | |
| SCHEMBL20748625 | 0.82 | KDM4E (0.56) | MAPTMEN1KMT2AGRM4SMARCA2 | |
| SCHEMBL12846645 | 0.79 | TRPA1 (0.44) | ALDH1A1GRM4HSD17B10SMARCA2SMARCA4 | |
| SCHEMBL24150569 | 0.78 | EGFR (0.57) | ALDH1A1MAPTMEN1KMT2AGRM4 | |
| SCHEMBL29066282 | 0.78 | ACVRL1 (0.61) | ALDH1A1MAPTMEN1KMT2AAR | |
| SCHEMBL26028729 | 0.77 | HSD17B10 (0.55) | ALDH1A1MAPTMEN1KMT2AAR | |
| SCHEMBL119685 | 0.77 | SMARCA2 (0.79) | MAPTMEN1KMT2ASMARCA2SMARCA4 | |
| SCHEMBL11042922 | 0.77 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AHSD17B10SMARCA2 | |
| SCHEMBL20619959 | 0.77 | SMARCA2 (0.55) | MAPTMEN1KMT2ASMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490360-B1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2011-03-16 | — | — | EP | disclosed |
| CN-1276920-C | Thiazolidinedione derivatives and pharmaceutical compositions containing the same | CHONG KUN DANG PHARM CORP (KR) | 2006-09-27 | — | — | CN | disclosed |
| EP-1490360-A4 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2006-07-05 | — | — | EP | disclosed |
| CN-1622945-A | Thiazolidinedione derivatives and pharmaceutical composition comprising the same | CHONG KUN DANG PHARM CORP (KR) | 2005-06-01 | — | — | CN | disclosed |
| EP-1490360-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2004-12-29 | — | — | EP | disclosed |
| US-6787551-B2 | ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2004-09-07 | — | — | US | disclosed |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-06-24 | — | — | US | disclosed |
| WO-2003080605-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | GLP1R, PPARD, SLC5A1 | ALDH1A1 196/4885MAPT 2380/4885MEN1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.